La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Rhythm Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Rhythm Pharmaceuticals' Il CEO è David Meeker, nominato in Jul2020, e ha un mandato di 4.08 anni. la retribuzione annua totale è $ 7.23M, composta da 9.7% di stipendio e 90.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.29% delle azioni della società, per un valore di $ 8.05M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 5.2 anni.
Informazioni chiave
David Meeker
Amministratore delegato
US$7.2m
Compenso totale
| Percentuale dello stipendio del CEO | 9.7% |
| Mandato del CEO | 4.1yrs |
| Proprietà del CEO | 0.3% |
| Durata media del management | 3.8yrs |
| Durata media del Consiglio di amministrazione | 5.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$261m |
| Mar 31 2024 | n/a | n/a | -US$274m |
| Dec 31 2023 | US$7m | US$705k | -US$185m |
| Sep 30 2023 | n/a | n/a | -US$186m |
| Jun 30 2023 | n/a | n/a | -US$182m |
| Mar 31 2023 | n/a | n/a | -US$181m |
| Dec 31 2022 | US$3m | US$652k | -US$181m |
| Sep 30 2022 | n/a | n/a | -US$181m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$166m |
| Dec 31 2021 | US$6m | US$630k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$15m | US$262k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$146m |
| Dec 31 2019 | US$287k | n/a | -US$141m |
| Sep 30 2019 | n/a | n/a | -US$133m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$282k | n/a | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$268k | n/a | -US$38m |
Compensazione vs Mercato: La retribuzione totale di David ($USD 7.23M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
David Meeker (70 yo)
4.1yrs
Mandato
US$7,230,457
Compensazione
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 4.1yrs | US$7.23m | 0.29% $ 8.0m | |
| CFO & Treasurer | 7.1yrs | US$2.31m | 0.16% $ 4.5m | |
| Chief Technical Officer | 4.1yrs | US$1.74m | 0.000050% $ 1.4k | |
| Executive VP & Head of International | 3.8yrs | US$1.74m | 0.057% $ 1.6m | |
| Executive VP & Head of North America | 3.8yrs | US$2.11m | 0.011% $ 312.6k | |
| Corporate Controller | 1.4yrs | Nessun dato | 0.0013% $ 36.2k | |
| Chief Scientific Officer | less than a year | Nessun dato | Nessun dato | |
| Head of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato | |
| Senior VP & General Counsel | 3.8yrs | Nessun dato | Nessun dato | |
| Vice President of Sales & Marketing | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 3.1yrs | Nessun dato | 0.022% $ 615.7k | |
| Senior VP & Head of Strategy | 2.5yrs | Nessun dato | Nessun dato |
3.8yrs
Durata media
51yo
Età media
Gestione esperta: Il team dirigenziale di RYTM è considerato esperto (durata media dell'incarico 3.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 8.8yrs | US$7.23m | 0.29% $ 8.0m | |
| Corporate Controller | 1.4yrs | Nessun dato | 0.0013% $ 36.2k | |
| Independent Director | 5.2yrs | US$283.77k | 0.0049% $ 136.9k | |
| Independent Director | 8.8yrs | US$308.77k | 0.0049% $ 136.9k | |
| Lead Independent Director | 11.4yrs | US$328.77k | 0.014% $ 400.1k | |
| Independent Director | 3.7yrs | US$298.77k | 0.0049% $ 136.9k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Chairman of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.1yrs | US$301.27k | 0.0049% $ 136.9k |
5.2yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RYTM sono considerati esperti (durata media dell'incarico 5.2 anni).